Robust clinical performance
Nutech's approved material reports 79.7% sensitivity, 87.9% specificity, and a ROC AUC of 0.927 in the identified Indian study population.
About Nutech
Advancing precision oncology through biomarker science.
Nutech Cancer Biomarkers India Pvt. Ltd. is a precision diagnostics company dedicated to improving patient outcomes through accurate cancer detection. The company translates scientific discoveries into clinically relevant diagnostic solutions.
Our scientific focusEarlier risk assessment through precision biomarker science
Our vision
To pioneer the future of precision oncology.
Nutech aims to transform cancer diagnostics through non-invasive, evidence-based molecular assays that enable earlier cancer risk assessment and support evidence-based clinical decision-making.
Driven by scientific excellence and analytical precision, the company develops innovative biomarker solutions intended to improve risk assessment, support doctors, and improve patient outcomes.
Why choose Nutech
Scientific performance, analytical discipline, and access.
Reported performance figures describe the referenced Indian study population and should be interpreted with the study design, intended use, limitations, and applicable regulatory status.
Objective predictive analytics
A multivariate logistic-regression approach combines biomarker information to support consistent classification and clinical review.
More than 10 years of experience
Nutech brings over a decade of technical experience in cancer biomarkers to its analytical and quality processes.
Wide sample access
Samples can be facilitated nationwide through verified collection and laboratory routes coordinated with the Nutech team.
The connected pathway
Every participant protects a different part of the journey.
Clear responsibilities support reliable sample handling, reporting, communication, and doctor-guided follow-up.
Patient
Receives clear preparation, consent, collection, reporting, and follow-up information.
Doctor
Uses the report alongside PSA, history, examination, and other appropriate clinical evidence.
Laboratory
Protects sample identity, quality control, processing, bioinformatics analysis, and report release.
Nutech network
Coordinates the biomarker pathway, verified access, professional participation, and patient communication.
Responsible communication
Evidence belongs with context and clinical interpretation.
SeroMark-1 supports risk assessment and biopsy-referral conversations; it does not diagnose prostate cancer or replace a doctor's assessment, PSA testing, imaging, or biopsy when those are appropriate.
Review the medical boundaries →Explore Nutech
Choose the pathway that fits your role.
Learn about the test, review partnership opportunities, or contact the Nutech team with a specific question.